The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual Report (2023),” providing a comprehensive overview of the adverse drug reaction (ADR) landscape in China for the year. The National Adverse Drug Reaction Monitoring Network received a total of 2,419,000 ADR/Event Report Forms, with an average of 1,716 reports per million people. Notably, 98.5% of county-level areas in China have reported ADRs/Events.
In the 2023 ADR/Event reports, there were 2.627 million suspected cases involving drugs, with chemical drugs accounting for 81.2%, biological products for 3.8%, and traditional Chinese medicines (TCMs) for 12.6%. Among the serious ADR/Event reports, 479,000 suspected drugs were involved, with chemical drugs at 84.9%, biological products at 6.7%, and TCMs at 5.4%.
The overall reporting of ADRs/Events in 2023 showed no significant change compared to 2022. From the patient age perspective, there was a slight increase in the proportion of children involved in ADRs, but overall safety remained good. The proportion of elderly patients aged 65 and above continued to rise, suggesting that clinical practice should continue to focus on strengthening the management of safe medication for this demographic. Anti-infective drugs topped the chemical category rankings, with their proportion rising for the first time after years of decline, likely due to the high incidence of respiratory infectious diseases in 2023. In the realm of biological products, macromolecular monoclonal antibody anti-tumor drugs remained the majority. The proportion of TCM in overall ADR/Event reports was on a downward trend, although the safe use of TCMs continues to be a necessary consideration.- Flcube.com
